05 Patients Serving patients with Current Clinical Trials RLY-1971 We are currently evaluating the safety and tolerability of RLY-1971 in a Phase 1 dose escalation study in patients with advanced or metastatic solid tumors. Learn More RLY-1971/GDC-1971 In August 2021, Genentech initiated the cohort of RLY-1971/GDC-1971, an inhibitor of SHP2, in combination with GDC-6036, an inhibitor of KRAS G12C, in a Phase 1b trial. Learn More RLY-4008 We are currently evaluating the safety and tolerability of RLY-4008 in a first-in-human dose escalation study in patients who have FGFR2 alterations in advanced solid tumors. Learn More For questions or interest in participating in our clinical trials, please email us. ClinicalTrials@relaytx.com Expanded Access Policy Relay Therapeutics is hyper-focused on bringing life-changing medicines to patients. Our goal is to provide access to our investigational therapies when it is appropriate. Read on to learn more. We are constantly working with patients, their families, caregivers, and advocacy groups to learn about the challenges patients experience in their daily lives and how we can best support them from a therapeutic perspective and beyond. Contact Us Who We Are Our Team Dynamo Platform Pipeline Patients Investors & Media Careers Contact Relay Therapeutics 399 Binney Street, 2nd Floor Cambridge, MA 02139 info@relaytx.com (617) 370-8837 © Relay Therapeutics 2020 Privacy Policy Terms of Use